Jennifer E. Cook net worth and biography

Jennifer Cook Biography and Net Worth

Director of BridgeBio Pharma

Jennifer E. Cook has served as a member of our Board of Directors since December 2019. She is currently the owner and principal of Jennifer Cook Consulting since July 2019. Ms. Cook has served as a member of the board of directors of Denali Therapeutics, Inc. (Nasdaq: DNLI) since November 2018, Ambys Medicines since March 2020, Gyroscope Therapeutics Limited since November 2020, and Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) since November 2020. Ms. Cook served as the Chief Executive Officer of GRAIL from January 2018 to June 2019. Previously, Ms. Cook was at Roche Pharmaceuticals and Genentech, where she held a number of senior management positions; from January 2017 to December 2017, Ms. Cook served as Senior Vice President, Global Head of Clinical Operations for Roche Pharmaceuticals; from September 2013 to December 2016, Ms. Cook served as Head of Region Europe Pharma for Roche Pharmaceuticals; and from July 2010 to September 2013, Ms. Cook served as the Senior Vice President, Business Unit Head Immunology and Ophthalmology for Genentech. Ms. Cook holds a B.A. in human biology and an M.S. in biology from Stanford University, as well as an M.B.A. from the Haas School of Business at the University of California, Berkeley. Ms. Cook’s qualifications to serve on our Board of Directors include her extensive experience as a senior management executive of healthcare and biotechnology companies, including as the senior vice president of one of the world’s largest healthcare companies.

What is Jennifer E. Cook's net worth?: The estimated net worth of Jennifer E. Cook is at least $438.70 thousand as of June 15th, 2026. Ms. Cook owns 6,589 shares of BridgeBio Pharma stock worth more than $438,702 as of June 18th. This net worth evaluation does not reflect any other investments that Ms. Cook may own. Learn More about Jennifer E. Cook's net worth.
How do I contact Jennifer E. Cook?: The corporate mailing address for Ms. Cook and other BridgeBio Pharma executives is 421 Kipling Street, Palo Alto CA, 94301. BridgeBio Pharma can also be reached via phone at (650) 391-9740. Learn More on Jennifer E. Cook's contact information.
Has Jennifer E. Cook been buying or selling shares of BridgeBio Pharma?: Over the course of the past ninety days, Jennifer E. Cook has sold $6,011,788.80 of BridgeBio Pharma stock. Most recently, Jennifer E. Cook sold 90,240 shares of the business's stock in a transaction on Monday, June 15th. The shares were sold at an average price of $66.62, for a transaction totalling $6,011,788.80. Following the completion of the sale, the director now directly owns 6,589 shares of the company's stock, valued at $438,959.18. Learn More on Jennifer E. Cook's trading history.
Who are BridgeBio Pharma's active insiders?: BridgeBio Pharma's insider roster includes Maricel Apuli (CAO), Jennifer Cook (Director), Douglas Dachille (Director), Ronald Daniels (Director), Andrea Ellis (Director), Neil Kumar (CEO), Andrew Lo (Director), Frank McCormick (Director), Richard Scheller (Insider), Randal Scott (Director), Brian Stephenson (CFO), Thomas Trimarchi (CFO), and Hannah Valantine (Director). Learn More on BridgeBio Pharma's active insiders.
Are insiders buying or selling shares of BridgeBio Pharma?: In the last year, insiders at the sold shares 45 times. They sold a total of 5,288,913 shares worth more than $260,511,538.93. The most recent insider tranaction occured on June, 15th when Director Jennifer E Cook sold 90,240 shares worth more than $6,011,788.80. Insiders at BridgeBio Pharma own 14.2% of the company. Learn More about insider trades at BridgeBio Pharma.
Information on this page was last updated on 6/15/2026.

Jennifer E. Cook Insider Trading History at BridgeBio Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/15/2026	Sell	90,240	$66.62	$6,011,788.80	6,589

Jennifer E. Cook Buying and Selling Activity at BridgeBio Pharma

BridgeBio Pharma Company Overview

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Today's Range

Now: $66.91

$65.59

$68.60

50 Day Range

MA: $69.89

$63.88

$77.93

2 Week Range

Now: $66.91

$40.19

$84.94

Volume

1,253,692 shs

Average Volume

2,758,865 shs

Market Capitalization

$13.10 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.97